A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies

• Status: Completed
• Trial end date: 2015-04-20
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zenyaku Kogyo Co., Ltd.

Criteria

Inclusion Criteria:

• Japanese males or females >= 20 years old

• Advanced (metastatic or unresectable) solid tumor

• ECOG performance status score of 0 or 1 and expected survival >12 weeks

• Recovered from hematological toxicities of prior cancer therapies

Exclusion Criteria:

• Previous treatment with PI3K inhibitor

• Serious/significant illnesses or underlying conditions, including diabetes or hepatic renal or CV disease.

• Other investigational agent within previous 4 weeks

• Participating in another clinical study